Chronic cough
Conditions
Interventions
Control Group:Patients receive oral gabapentin capsules only. The initial dose is 50 mg per day, administered twice daily (25 mg in the morning and 25 mg in the evening). After three days, the dose is
Milnacipran Group:Patients receive oral milnacipran hydrochloride tablets only. The initial dose is 50 mg per day, administered twice daily (25 mg in the morning and 25 mg in the evening). After three
Milnacipran + CBT Group:Patients receive oral milnacipran hydrochloride tablets (administered as in the Milnacipran Group) combined with CBT (Cognitive Behavioral Therapy) once per week, with each ses
Sponsors
Tongji Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: a. Age between 18 and 70 years (inclusive), with no restriction on gender. b. Cough is the primary symptom, with a duration of more than 2 months, and chest imaging showing no significant abnormalities. c. Patients with refractory cough who, after a comprehensive evaluation following the Guidelines for the Diagnosis and Treatment of Cough (2021) issued by the Asthma Group of the Chinese Thoracic Society, either have no identified cause or experience no relief despite treatment for a known cause. d. Total cough symptom score >= 3. e. Participants fully understand the purpose of the study, are willing and able to comply with the study requirements, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: a. Pregnant or breastfeeding women. b. Individuals who are currently smoking or have quit smoking within the past 2 years. c. History of psychological therapy or psychiatric medication use within the past 3 months. d. History of new-onset respiratory tract infection within the past 8 weeks. e. Contraindications to or history of allergy to Milnacipran. f. Presence of severe underlying diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough Visual Analog Scale (VAS) Score;24-Hour Cough Frequency Record;Cough Symptom Score (CSS);Leicester Cough Questionnaire (LCQ);Hull Airway Reflux Questionnaire (HARQ);Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ);Capsaicin Cough Sensitivity Test (Capsaicin Cough Challenge);Psychological Assessment Scales;Brain Functional Magnetic Resonance Imaging (fMRI); | — |
Countries
China
Contacts
Public ContactTongyangzi Zhang
Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Outcome results
None listed